CapsoVision (CV) Current Deferred Revenue (2024 - 2025)
CapsoVision (CV) reported Current Deferred Revenue of $177000.0 for Q4 2025, up 34.09% on a YoY basis from $132000.0 in Q4 2024, and up 66.98% sequentially from $106000.0 in Q3 2025.
CapsoVision (CV) Current Deferred Revenue (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Current Deferred Revenue data on file, last reported at $177000.0 in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue rose 34.09% year-over-year to $177000.0; the trailing twelve-month figure through Dec 2025 stood at $177000.0 (up 34.09% YoY), and the FY2025 full-year result was $177000.0, up 34.09% from the prior year.
- Current Deferred Revenue advanced to $177000.0 in Q4 2025, from $106000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $177000.0 in Q4 2025 to a low of $97000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Dec 31, 2024 | 132,000.00 |